Renal clearance transport mechanisms for epirubicin and epirubicinol

Renal clearance transport mechanisms for epirubicin and epirubicinol refers to the physiological pathways and specific membrane proteins involved in the elimination of the anthracycline antineoplastic agent epirubicin and its primary metabolite, epirubicinol, via the kidneys. While the majority of epirubicin is excreted through the hepatobiliary system, approximately 10-15% of the dose is cleared renally through a combination of glomerular filtration and active tubular secretion (FDA Ellence Label; Robert, J., 1994, Clinical Pharmacokinetics). The active transport component is primarily mediated by members of the ATP-binding cassette (ABC) transporter family, most notably P-glycoprotein (ABCB1), Multidrug Resistance-associated Protein 2 (ABCC2), and Breast Cancer Resistance Protein (ABCG2), which are expressed on the apical membrane of renal proximal tubule cells (Giacomini, K. M., et al., 2010, Nature Reviews Drug Discovery; Sharom, F. J., 2008, Pharmacogenomics). Epirubicinol, formed by the reduction of epirubicin by carbonyl reductases, is also a substrate for these efflux transporters (Licata, S., et al., 2000, Current Medicinal Chemistry). Understanding these mechanisms is vital for predicting drug-drug interactions, as co-administration with inhibitors of these transporters (e.g., verapamil or cyclosporine) can decrease renal clearance and increase the risk of systemic toxicities such as myelosuppression and cardiotoxicity (Marchetti, S., et al., 2007, Current Drug Metabolism). Furthermore, dosage adjustments may be necessary in patients with significant renal impairment to maintain therapeutic efficacy while minimizing adverse effects (FDA Ellence Label).

Other names

Renal excretion of epirubicinEpirubicin renal transportEpirubicinol renal clearance

Active tubular secretion and glomerular filtration mediated by ABC transporters (ABCB1, ABCC2, ABCG2) and potentially SLC transporters.